Phase 1
Recruiting
Locally Advanced
Study CP-MGC018-02 is a study of MGC018 in combination with lorigerlimab. The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally…